ATYR 1940

Drug Profile

ATYR 1940

Alternative Names: ATYR1940; HRS(1-506); HRS(I-506); Resolaris

Latest Information Update: 17 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator aTyr Pharma
  • Class Amino acyl-tRNA synthetases; Aminoacyltransferases; Biological proteins; Peptides; Proteins
  • Mechanism of Action Histidine-tRNA ligase modulators; T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Facioscapulohumeral muscular dystrophy; Limb girdle muscular dystrophies
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Facioscapulohumeral muscular dystrophy; Limb girdle muscular dystrophies
  • Preclinical Interstitial lung diseases
  • Research Duchenne muscular dystrophy

Most Recent Events

  • 15 Aug 2017 Adverse events data from the phase I/II 005 and 006 trials in Facioscapulohumeral muscular dystrophy released by aTYR Pharma
  • 15 Aug 2017 Efficacy data from phase I/II 005 and 006 trials in Facioscapulohumeral muscular dystrophy released by aTYR Pharma
  • 14 Aug 2017 aTyr Pharma completes the phase I/II 005 extension trial for Facioscapulohumeral muscular dystrophy in Italy, USA and Netherlands (EudraCT2015-001912-36) (NCT02531217) before August 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top